Related Experiment Video
Updated: Jan 4, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection
Jessie R Maxwell1, Robin K Ohls2
1Department of Pediatrics, University of New Mexico, Albuquerque, NM.
Abstract:
Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been studied as red blood cell growth factors in preterm and term infants for more than 30 years. Recently, studies have focused on the potential neuroprotective effects of ESAs. In this review, we summarize preclinical animal models and recent clinical trials that provide evidence for ESAs as potential treatments to improve neurodevelopmental outcomes in preterm and term infants.
Related Concept Videos
Drug Dosing: Infants and Children
Erythropoiesis

